ArticleClinical kidney journal2014
Anticoagulation in chronic kidney disease patients-the practical aspects.
Article in Clinical kidney journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06543927 (Frequncy and Risk Factors of Bleeding in Patients With Chronic Kidney Disease Receiving Antigoagulants), which is not on this map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Frequncy and Risk Factors of Bleeding in Patients With Chronic Kidney Disease Receiving Antigoagulants
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Management of antithrombotic therapies in kidney transplantation candidates and recipients: an ERBP clinical practice document by the DESCaRTES Working Group of ERA and the EKITA Committee of ESOT.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Guideline
- A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease.Journal of nephrology · 2022Pooled it
- A Survey on Anticoagulation Practices in Patients with Chronic Kidney Disease in Saudi Arabia.Journal of clinical medicine · 2026Article
- Heparin Anticoagulant Therapy and Its Monitoring.Biomolecules · 2026Review
- Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism.Nature reviews. Cardiology · 2025Review
- Structure-based design and synthesis of novel FXIa inhibitors targeting the S2' subsite for enhanced antithrombotic efficacy.Molecular diversity · 2025Article
- Management of anticoagulation in patients with atrial fibrillation and renal dysfunction: A systematic review.World journal of experimental medicine · 2025Article
- Prevalence and predictors of potentially inappropriate medication in older adults hospitalized with cardiovascular disease.Journal of family medicine and primary care · 2025Article
- Anticoagulation in Patients with End-Stage Renal Disease: A Critical Review.Healthcare (Basel, Switzerland) · 2025Review
- BIOCHEMICAL INVESTIGATION OF THE ANTICOAGULANT ACTIVITY OF SULFONATED POLYMERS.Journal of undergraduate chemistry research · 2025Article
- Diagnosis and management of ACS in patients with ESRD on haemodialysis: a comprehensive review.The British journal of cardiology · 2025Article
- Anticoagulation in Chronic Kidney Disease.Drugs · 2024Review
- Heparin-induced thrombocytopenia with very high antibody titer is associated with slower platelet recovery and higher risk of thrombosis.International journal of hematology · 2024Article
- Management of patients with heart failure and chronic kidney disease.Heart failure reviews · 2024Review
- Effectiveness, Safety, and Costs of Thromboprophylaxis with Enoxaparin or Unfractionated Heparin Among Medical Inpatients With Chronic Obstructive Pulmonary Disease or Heart Failure.Journal of health economics and outcomes research · 2024Article
- Management and Outcomes of Pulmonary Embolism in the Oldest-Old.International journal of general medicine · 2024Article
- The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis.Cancers · 2023Review
- The Risk of Venous Thromboembolism in Korean Patients with Breast Cancer: A Single-Center Experience.Cancers · 2023Article
- Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Review
- Safety and Feasibility of Immunoadsorption with Heparin Anticoagulation in Preparation of ABO-Incompatible Kidney Transplantation: A Retrospective Single-Center Study.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an increasing awareness about the risks of arterial and venous thromboembolism (TE) in hospital patients and general public which has led to consideration of thrombosis prevention measures in earnest. Early recognition of the symptoms of TE disease has led to timely administration of antiplatelet and anticoagulant drugs, translating to better outcome in many of these patients. In this respect, patients with chronic kidney disease (CKD) represent a special group. They indeed represent a high-risk group for thrombosis both in the cardiovascular territory and also in the venous circulation. At the same time, abnormalities in the platelet membranes put them at risk of bleeding which is significantly more than other patients with chronic diseases. Anticoagulation may be ideal to prevent the former, but the co-existing bleeding risk and also that the commonly used drugs for inhibiting coagulation are eliminated by renal pathways pose additional problems. In this review, we try to explain the complex thrombotic-haemorrhagic state of chronic kidney disease patients, and practical considerations for the management of anticoagulation in them with a focus on heparins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.